240 related articles for article (PubMed ID: 34325057)
21. [Clinical significance of minimal residual disease in B-lineage acute lymphoblastic leukemia pediatric patients with different fusion gene backgrounds].
Wei T; Chen XJ; Zhang LY; Zhang AL; Zhu XF
Zhongguo Dang Dai Er Ke Za Zhi; 2020 Dec; 22(12):1279-1285. PubMed ID: 33327998
[TBL] [Abstract][Full Text] [Related]
22. Fusion gene transcripts and Ig/TCR gene rearrangements are complementary but infrequent targets for PCR-based detection of minimal residual disease in acute myeloid leukemia.
Boeckx N; Willemse MJ; Szczepanski T; van der Velden VH; Langerak AW; Vandekerckhove P; van Dongen JJ
Leukemia; 2002 Mar; 16(3):368-75. PubMed ID: 11896540
[TBL] [Abstract][Full Text] [Related]
23. CD304/neuropilin-1 is a very useful and dependable marker for the measurable residual disease assessment of B-cell precursor acute lymphoblastic leukemia.
Gudapati P; Khanka T; Chatterjee G; Ghogale S; Badrinath Y; Deshpande N; Patil J; Narula G; Shetty D; Banavali S; Patkar NV; Gujral S; Subramanian PG; Tembhare PR
Cytometry B Clin Cytom; 2020 Jul; 98(4):328-335. PubMed ID: 31944572
[TBL] [Abstract][Full Text] [Related]
24. BCR-ABL, ETV6-RUNX1 and E2A-PBX1: prevalence of the most common acute lymphoblastic leukemia fusion genes in Mexican patients.
Jiménez-Morales S; Miranda-Peralta E; Saldaña-Alvarez Y; Perez-Vera P; Paredes-Aguilera R; Rivera-Luna R; Velázquez-Cruz R; Ramírez-Bello J; Carnevale A; Orozco L
Leuk Res; 2008 Oct; 32(10):1518-22. PubMed ID: 18455790
[TBL] [Abstract][Full Text] [Related]
25. TEL-AML1 fusion RNA as a new target to detect minimal residual disease in pediatric B-cell precursor acute lymphoblastic leukemia.
Cayuela JM; Baruchel A; Orange C; Madani A; Auclerc MF; Daniel MT; Schaison G; Sigaux F
Blood; 1996 Jul; 88(1):302-8. PubMed ID: 8704188
[TBL] [Abstract][Full Text] [Related]
26. Characterization of Immunophenotypic Aberrancies with Respect to Common Fusion Transcripts in B-Cell Precursor Acute Lymphoblastic Leukemia: A Report of 986 Indian Patients.
Gupta DG; Varma N; Naseem S; Sachdeva MUS; Bose P; Binota J; Kumar A; Gupta M; Rana P; Sonam P; Malhotra P; Trehan A; Khadwal A; Varma S
Turk J Haematol; 2022 Feb; 39(1):1-12. PubMed ID: 34617433
[TBL] [Abstract][Full Text] [Related]
27. Emerging molecular subtypes and therapies in acute lymphoblastic leukemia.
Davis K; Sheikh T; Aggarwal N
Semin Diagn Pathol; 2023 May; 40(3):202-215. PubMed ID: 37120350
[TBL] [Abstract][Full Text] [Related]
28. [Clinical Significance of Minimal Residual Disease in Pediatric Patients with
Xue YJ; Lu AD; Wang Y; Jia YP; Zuo YX; Zhang LP
Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2023 Oct; 31(5):1303-1308. PubMed ID: 37846676
[TBL] [Abstract][Full Text] [Related]
29. High frequency and poor prognosis of late childhood BCR-ABL-positive and MLL-AF4-positive ALL define the need for advanced molecular diagnostics and improved therapeutic strategies in pediatric B-ALL in Pakistan.
Iqbal Z; Akhtar T; Awan T; Aleem A; Sabir N; Rasool M; Absar M; Akram AM; Shammas MA; Shah IH; Khalid M; Taj AS; Jameel A; Alanazi A; Gill AT; Hashmi JA; Hussain A; Sabar MF; Khalid AM; Qazi MH; Karim S; Siddiqi MH; Mahmood A; Iqbal M; Saeed A; Irfan MI
Mol Diagn Ther; 2015 Oct; 19(5):277-87. PubMed ID: 26266519
[TBL] [Abstract][Full Text] [Related]
30. Measurable residual disease analysis in paediatric acute lymphoblastic leukaemia patients with ABL-class fusions.
Venn NC; Huang L; Hovorková L; Muskovic W; Wong M; Law T; Heatley SL; Khaw SL; Revesz T; Dalla Pozza L; Shaw PJ; Fraser C; Moore AS; Cross S; Bendak K; Norris MD; Henderson MJ; White DL; Cowley MJ; Trahair TN; Zuna J; Sutton R
Br J Cancer; 2022 Sep; 127(5):908-915. PubMed ID: 35650277
[TBL] [Abstract][Full Text] [Related]
31. Standardized RT-PCR analysis of fusion gene transcripts from chromosome aberrations in acute leukemia for detection of minimal residual disease. Report of the BIOMED-1 Concerted Action: investigation of minimal residual disease in acute leukemia.
van Dongen JJ; Macintyre EA; Gabert JA; Delabesse E; Rossi V; Saglio G; Gottardi E; Rambaldi A; Dotti G; Griesinger F; Parreira A; Gameiro P; Diáz MG; Malec M; Langerak AW; San Miguel JF; Biondi A
Leukemia; 1999 Dec; 13(12):1901-28. PubMed ID: 10602411
[TBL] [Abstract][Full Text] [Related]
32. Five most common prognostically important fusion oncogenes are detected in the majority of Pakistani pediatric acute lymphoblastic leukemia patients and are strongly associated with disease biology and treatment outcome.
Awan T; Iqbal Z; Aleem A; Sabir N; Absar M; Rasool M; Tahir AH; Basit S; Khalid AM; Sabar MF; Asad S; Ali AS; Mahmood A; Akram M; Saeed T; Saleem A; Mohsin D; Shah IH; Khalid M; Asif M; Haq R; Iqbal M; Akhtar T
Asian Pac J Cancer Prev; 2012; 13(11):5469-75. PubMed ID: 23317202
[TBL] [Abstract][Full Text] [Related]
33. Detection of Immunoglobulin Heavy Chain Gene Clonality by Next-Generation Sequencing for Minimal Residual Disease Monitoring in B-Lymphoblastic Leukemia.
Shin S; Hwang IS; Kim J; Lee KA; Lee ST; Choi JR
Ann Lab Med; 2017 Jul; 37(4):331-335. PubMed ID: 28445014
[TBL] [Abstract][Full Text] [Related]
34. Outcome and Prognostic Factors for
Lee JW; Kim SK; Jang PS; Chung NG; Jeong DC; Kim M; Cho B; Kim HK
Cancer Res Treat; 2017 Apr; 49(2):446-453. PubMed ID: 27506214
[TBL] [Abstract][Full Text] [Related]
35. Early MRD response as a prognostic factor in adult patients with acute lymphoblastic leukemia.
Šálek C; Folber F; Froňková E; Procházka B; Marinov I; Cetkovský P; Mayer J; Doubek M;
Eur J Haematol; 2016 Mar; 96(3):276-84. PubMed ID: 25997106
[TBL] [Abstract][Full Text] [Related]
36. RT-PCR and real-time PCR analysis of E2A-PBX1, TEL-AML1, mBCR-ABL and MLL-AF4 fusion gene transcripts in de novo B-lineage acute lymphoblastic leukaemia patients in south India.
Sudhakar N; Rajalekshmy KR; Rajkumar T; Nancy KN
J Genet; 2011 Aug; 90(2):349-53. PubMed ID: 21869488
[No Abstract] [Full Text] [Related]
37. Hematological characteristics, cytogenetic features, and post-induction measurable residual disease in thymic stromal lymphopoietin receptor (TSLPR) overexpressed B-cell acute lymphoblastic leukemia in an Indian cohort.
Virk H; Rana S; Sharma P; Bose PL; Yadav DD; Sachdeva MUS; Varma N; Trehan A; Lad D; Khadwal AR; Malhotra P; Sreedharanunni S
Ann Hematol; 2021 Aug; 100(8):2031-2041. PubMed ID: 34159401
[TBL] [Abstract][Full Text] [Related]
38. High frequency of heat shock protein 27 overexpression is a highly effective, high-coverage marker for minimal residual disease detection in children with B-cell acute lymphoblastic leukemia.
Chou SW; Su YH; Lu MY; Chang HH; Yang YL; Lin DT; Lin KH; Coustan-Smith E; Jou ST
Pediatr Blood Cancer; 2023 Jan; 70(1):e29990. PubMed ID: 36250996
[TBL] [Abstract][Full Text] [Related]
39. TCRB gene rearrangements in childhood and adult precursor-B-ALL: frequency, applicability as MRD-PCR target, and stability between diagnosis and relapse.
van der Velden VH; Brüggemann M; Hoogeveen PG; de Bie M; Hart PG; Raff T; Pfeifer H; Lüschen S; Szczepański T; van Wering ER; Kneba M; van Dongen JJ
Leukemia; 2004 Dec; 18(12):1971-80. PubMed ID: 15470492
[TBL] [Abstract][Full Text] [Related]
40. Minimal residual disease analysis in children with t(12;21)-positive acute lymphoblastic leukemia: comparison of Ig/TCR rearrangements and the genomic fusion gene.
Metzler M; Mann G; Monschein U; Lodzinski M; Gall C; Flohr T; Viehmann S; Langer T; Schrappe M; Gadner H; Haas OA; Panzer-Grümayer ER
Haematologica; 2006 May; 91(5):683-6. PubMed ID: 16627248
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
